| Abstract | This article reviews placebo-controlled studies addressing drug efficacy for the cognitive deficits of Alzheimer's disease. Efforts to compensate for the presynaptic cholinergic deficiency in Alzheimer's disease by pharmacologically inhibiting acetylcholine degradation have been successful in several clinical trials. Two cholinesterase inhibitors are available for Alzheimer's disease, and others most likely will soon be available. Cholinesterase inhibitors represent the only therapy currently approved for the treatment of Alzheimer's disease. The antioxidant drugs alpha-tocopherol (vitamin E) and selegiline have been demonstrated marginally superior to placebo for slowing functional deterioration in patients with moderately advanced Alzheimer's disease. Epidemiologic studies suggest protective effects against Alzheimer's disease from postmenopausal estrogen replacement and nonsteroidal anti-inflammatory drugs. Placebo-controlled studies prospectively evaluating the hypotheses generated by these epidemiologic studies are ongoing. |
| Authors | E R Peskind
(Affiliation: Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, and Veterans Affairs Puget Sound Health Care System, Seattle, USA.)
|
| Journal | The Journal of clinical psychiatry
(J Clin Psychiatry)
Vol. 59 Suppl 9
Pg. 22-7
( 1998)
ISSN: 0160-6689 UNITED STATES |
| PMID | 9720483
(Publication Type: Journal Article, Review)
|
| Chemical References |
- Antioxidants
- Cholinesterase Inhibitors
- Indans
- Nootropic Agents
- Piperidines
- Placebos
- donepezil
- Tacrine
- Trichlorfon
|
| Topics |
- Alzheimer Disease
(drug therapy)
- Antioxidants
(therapeutic use)
- Cholinesterase Inhibitors
(therapeutic use)
- Clinical Trials as Topic
- Cognition Disorders
(drug therapy)
- Estrogen Replacement Therapy
- Humans
- Indans
(therapeutic use)
- Nootropic Agents
(therapeutic use)
- Piperidines
(therapeutic use)
- Placebos
- Tacrine
(therapeutic use)
- Treatment Outcome
- Trichlorfon
(therapeutic use)
|
